AU2002309038A1 - Compositions for transmucosal administration containing coenzyme Q as the active ingredient - Google Patents

Compositions for transmucosal administration containing coenzyme Q as the active ingredient

Info

Publication number
AU2002309038A1
AU2002309038A1 AU2002309038A AU2002309038A AU2002309038A1 AU 2002309038 A1 AU2002309038 A1 AU 2002309038A1 AU 2002309038 A AU2002309038 A AU 2002309038A AU 2002309038 A AU2002309038 A AU 2002309038A AU 2002309038 A1 AU2002309038 A1 AU 2002309038A1
Authority
AU
Australia
Prior art keywords
compositions
active ingredient
transmucosal administration
administration containing
containing coenzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002309038A
Other versions
AU2002309038B2 (en
Inventor
Kenji Fujii
Takayoshi Hidaka
Kazunori Hosoe
Taizo Kawabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Priority claimed from PCT/JP2002/004476 external-priority patent/WO2002092067A1/en
Publication of AU2002309038A1 publication Critical patent/AU2002309038A1/en
Application granted granted Critical
Publication of AU2002309038B2 publication Critical patent/AU2002309038B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002309038A 2001-05-10 2002-05-08 Compositions for transmucosal administration containing coenzyme Q as the active ingredient Ceased AU2002309038B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-139605 2001-05-10
JP2001139605 2001-05-10
PCT/JP2002/004476 WO2002092067A1 (en) 2001-05-10 2002-05-08 Compositions for transmucosal administration containing coenzyme q as the active ingredient

Publications (2)

Publication Number Publication Date
AU2002309038A1 true AU2002309038A1 (en) 2003-05-01
AU2002309038B2 AU2002309038B2 (en) 2007-05-17

Family

ID=18986353

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002309038A Ceased AU2002309038B2 (en) 2001-05-10 2002-05-08 Compositions for transmucosal administration containing coenzyme Q as the active ingredient

Country Status (9)

Country Link
US (1) US7754205B2 (en)
EP (1) EP1388340B1 (en)
KR (2) KR20060103288A (en)
CN (1) CN100438862C (en)
AT (1) ATE480231T1 (en)
AU (1) AU2002309038B2 (en)
CA (1) CA2443191A1 (en)
DE (1) DE60237597D1 (en)
WO (1) WO2002092067A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3742602B2 (en) * 2001-05-09 2006-02-08 株式会社カネカ Stable solution of reduced coenzyme Q
TW200304372A (en) * 2002-03-20 2003-10-01 Kanegafuchi Chemical Ind Compositions for diabetes
TWI322008B (en) * 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10
KR20060100402A (en) * 2003-10-31 2006-09-20 가부시키가이샤 가네카 Composition containing reduced coenzyme q
KR101420034B1 (en) 2004-01-22 2014-07-17 유니버시티 오브 마이애미 Topical co-enzyme q10 formulations and methodns of use
US20090081683A1 (en) * 2005-11-29 2009-03-26 Genelink, Inc. Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin
US20090246185A1 (en) * 2006-03-13 2009-10-01 Kaneka Corporation Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent
EP2011498A4 (en) * 2006-04-10 2009-11-11 Mitsubishi Gas Chemical Co Brain function-improving agent, and functional food containing the improving agent
JP2009536215A (en) * 2006-05-02 2009-10-08 ユニバーシティ オブ マイアミ Topical coenzyme Q10 formulation and treatment of pain, fatigue, and wounds
EP3015104A1 (en) 2008-04-11 2016-05-04 Berg LLC Methods and use of inducing apoptosis in cancer cells
KR20120060945A (en) 2009-05-11 2012-06-12 버그 바이오시스템즈, 엘엘씨 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
CN102503798B (en) * 2011-11-16 2014-07-16 中国农业科学院蜜蜂研究所 Method for extracting coenzyme Q 10 from bee pollen and application thereof
KR101581508B1 (en) * 2012-12-03 2015-12-31 가톨릭대학교 산학협력단 Composition for preventing or treating inflammatory disease or immunological rejection comprising coenzyme Q10 as an effective component
WO2014088301A1 (en) * 2012-12-03 2014-06-12 가톨릭대학교 산학협력단 Composition for preventing or treating inflammatory diseases or immunological rejection comprising coenzyme q10 as active ingredient
SG11201508272YA (en) 2013-04-08 2015-11-27 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
CN110769818A (en) 2017-05-17 2020-02-07 博格有限责任公司 Use of coenzyme Q10 preparation for treating and preventing epidermolysis bullosa
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH655005A5 (en) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY.
US5378461A (en) * 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
JP3889481B2 (en) * 1996-08-16 2007-03-07 株式会社カネカ Pharmaceutical composition
US6228891B1 (en) * 1997-02-12 2001-05-08 Mse Pharmazeutika Gmbh Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
DE19802050A1 (en) 1998-01-21 1999-07-22 Labtec Gmbh Peridontal treatment composition providing local oral release of coenzyme Q10
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6200550B1 (en) 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
DE19905880A1 (en) 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
DE19905879A1 (en) * 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Ubiquinon Qn used to treat pain
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
IT1316997B1 (en) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF VASCULOPATHIES, WHICH INCLUDES PROPIONYL L-CARNITINE AND COENZYME Q10.
US6686485B2 (en) * 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
JP3742602B2 (en) * 2001-05-09 2006-02-08 株式会社カネカ Stable solution of reduced coenzyme Q
US7708990B2 (en) * 2004-03-23 2010-05-04 Kaneka Corporation Coenzyme Q compositions persisting in blood

Similar Documents

Publication Publication Date Title
IL162213A0 (en) Pharmaceutical compositions containing active vitamin d compounds
AU781269C (en) Pharmaceutical compositions
AU2002313236A1 (en) Medicinal compositions
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
AU2001250420A1 (en) Pharmaceutical compositions
AU2002363361A1 (en) Pharmaceutical compositions containing oxybutynin
AU2001274307A1 (en) Pharmaceutical compositions
AU2002341205A1 (en) Pharmaceutical compositions comprising cyclosporin
AU2002257582A1 (en) Pharmaceutical formulation
AU2002337803A1 (en) Sustained release pharmaceutical compositions
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002258221A1 (en) Medicinal composition
AU2002214324A1 (en) Medicinal compositions
AU2002340573A1 (en) Powdery active ingredient formulations
AU2001273919A1 (en) Pharmaceutical compositions
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
AU4431400A (en) Anticancer agents containing ep1 antagonists as the active ingredient
AU2002357010A1 (en) Stabilized active oxygen compositions
AU2003216503A1 (en) Stable pharmaceutical compositions
AU2002354460A1 (en) Medicinal composition
EP1199076A3 (en) Medicament containing tocotrienol as active component
HUP0303714A3 (en) Pharmaceutical compositions for dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient